Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Bibliografske podrobnosti
Main Authors:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
Format:	Conference item
Jezik:	English
Izdano:	European Respiratory Society 2020

Podobne knjige/članki

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
od: Moran, AM, et al.
Izdano: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
od: Shrimanker, R, et al.
Izdano: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
od: Charlene Desaintjean, et al.
Izdano: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
od: Bel, E, et al.
Izdano: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
od: Andrea Portacci, et al.
Izdano: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
od: Bel, E, et al.
Izdano: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
od: S. K. Zyryanov, et al.
Izdano: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
od: Pavord, I, et al.
Izdano: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
od: Arian Ghassemian, et al.
Izdano: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
od: Pavord, I
Izdano: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
od: Haldar, P, et al.
Izdano: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
od: Howell, I, et al.
Izdano: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
od: Erminia Ridolo, et al.
Izdano: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
od: Kayser MZ, et al.
Izdano: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
od: Ortega, H, et al.
Izdano: (2014)

Mepolizumab for eosinophilic COPD
od: Sciurba, F, et al.
Izdano: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
od: Osamu Matsuno, et al.
Izdano: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
od: Yancey, S, et al.
Izdano: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
od: Menzella F, et al.
Izdano: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
od: Mirhojjat Khorasanizadeh, et al.
Izdano: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
od: Gómez-Bastero Fernández A, et al.
Izdano: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
od: Gunsoy, N, et al.
Izdano: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
od: Laura J. Walsh, et al.
Izdano: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
od: Alistair Cook, et al.
Izdano: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
od: Howell, I, et al.
Izdano: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
od: Imran Howell, et al.
Izdano: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
od: Stephen G. Noorduyn, et al.
Izdano: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
od: Francesco Menzella, et al.
Izdano: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
od: Couillard, S, et al.
Izdano: (2021)

Asthma in pregnancy: An update
od: Couillard, S, et al.
Izdano: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
od: Shrimanker, R, et al.
Izdano: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
od: Ortega, H, et al.
Izdano: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
od: Gittins, A, et al.
Izdano: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
od: Steven W. Yancey, et al.
Izdano: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
od: Lisha Li, et al.
Izdano: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
od: Kohei Somekawa, et al.
Izdano: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
od: Andrew Menzies-Gow, et al.
Izdano: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
od: Shrimanker, R, et al.
Izdano: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
od: Oliver, ME, et al.
Izdano: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
od: Carlos Martínez-Rivera, et al.
Izdano: (2021-01-01)